$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 6,900 | 0 | 95,327 | 88.4 K to 95.3 K (+7.80 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | A | 30.17 | 46,300 | 1,396,871 | 46,300 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Grant | A | 0.00 | 7,900 | 0 | 62,423 | 54.5 K to 62.4 K (+14.49 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 30.17 | 41,300 | 1,246,021 | 41,300 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 6,900 | 0 | 77,800 | 70.9 K to 77.8 K (+9.73 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | A | 30.17 | 47,300 | 1,427,041 | 47,300 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Grant | A | 0.00 | 7,900 | 0 | 104,400 | 96.5 K to 104.4 K (+8.19 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | A | 30.17 | 47,300 | 1,427,041 | 47,300 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Grant | A | 0.00 | 7,900 | 0 | 136,977 | 144.9 K to 137 K (-5.45 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 27.60 | 1,641 | 45,292 | 88,427 | 90.1 K to 88.4 K (-1.82 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 26.81 | 359 | 9,625 | 90,068 | 90.4 K to 90.1 K (-0.40 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 27.56 | 1,400 | 38,584 | 54,523 | 55.9 K to 54.5 K (-2.50 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 26.43 | 300 | 7,929 | 55,923 | 56.2 K to 55.9 K (-0.53 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 27.63 | 1,300 | 35,919 | 70,900 | 72.2 K to 70.9 K (-1.80 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 26.87 | 400 | 10,748 | 72,200 | 72.6 K to 72.2 K (-0.55 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 27.62 | 1,600 | 44,192 | 96,500 | 98.1 K to 96.5 K (-1.63 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 26.81 | 400 | 10,724 | 98,100 | 98.5 K to 98.1 K (-0.41 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 27.61 | 1,900 | 52,459 | 129,077 | 131 K to 129.1 K (-1.45 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 26.92 | 600 | 16,152 | 130,977 | 131.6 K to 131 K (-0.46 %) |
Jan 04 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 6,251 | |
Jan 04 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 72,600 | 62.6 K to 72.6 K (+15.97 %) |
Jan 03 2017 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | P | 25.50 | 4,000 | 102,000 | 4,000 | 0 to 4 K |
Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 3.88 | 4,561 | 17,697 | 0 | |
Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 10,000 | 52,800 | 6,761 | |
Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 3.88 | 4,561 | 17,697 | 90,427 | 85.9 K to 90.4 K (+5.31 %) |
Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 10,000 | 52,800 | 85,866 | 75.9 K to 85.9 K (+13.18 %) |
Dec 22 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | J | 0.00 | 2,190 | 0 | 3,814 | 1.6 K to 3.8 K (+134.85 %) |
Dec 22 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 747,127 | 0 | 0 | 747.1 K to 0 (-100.00 %) |
Dec 19 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | M | 5.88 | 127,122 | 747,477 | 0 | |
Dec 19 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Payment of Exercise | F | 33.98 | 22,000 | 747,560 | 105,122 | 127.1 K to 105.1 K (-17.31 %) |
Dec 19 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Buy | M | 5.88 | 127,122 | 747,477 | 127,122 | 0 to 127.1 K |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | X | 5.88 | 3,384 | 19,898 | 0 | |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | X | 5.88 | 180,518 | 1,061,446 | 0 | |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | S | 30.96 | 643 | 19,907 | 747,127 | 747.8 K to 747.1 K (-0.09 %) |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | X | 5.88 | 3,384 | 19,898 | 747,770 | 744.4 K to 747.8 K (+0.45 %) |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | S | 30.96 | 34,285 | 1,061,464 | 744,386 | 778.7 K to 744.4 K (-4.40 %) |
Dec 09 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | X | 5.88 | 180,518 | 1,061,446 | 778,671 | 598.2 K to 778.7 K (+30.18 %) |
Dec 05 2016 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 35.04 | 400,000 | 14,016,000 | 400,000 | |
Dec 05 2016 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 62,800 | 0 | 62,800 | 0 to 62.8 K |
Nov 21 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | J | 0.00 | 1,624 | 0 | 1,624 | 0 to 1.6 K |
Nov 21 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 6,980 | 0 | 598,153 | 605.1 K to 598.2 K (-1.15 %) |
Nov 21 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 693,020 | 0 | 605,133 | 1.3 M to 605.1 K (-53.39 %) |
Nov 18 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 38.05 | 379,464 | 14,438,605 | 0 | 379.5 K to 0 (-100.00 %) |
Nov 18 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 39.13 | 41,112 | 1,608,713 | 379,464 | 420.6 K to 379.5 K (-9.78 %) |
Nov 18 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 41.39 | 32,929 | 1,362,931 | 420,576 | 453.5 K to 420.6 K (-7.26 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 5,606 | 28,478 | 109,027 | |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 15,976 | 84,353 | 21,524 | |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 9,375 | 49,500 | 28,125 | |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 37,500 | 198,000 | 12,500 | |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.88 | 31,543 | 185,473 | 18,457 | |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.19 | 100,000 | 3,219,000 | 214,084 | 314.1 K to 214.1 K (-31.84 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 5,606 | 28,478 | 314,084 | 308.5 K to 314.1 K (+1.82 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 15,976 | 84,353 | 308,478 | 292.5 K to 308.5 K (+5.46 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 9,375 | 49,500 | 292,502 | 283.1 K to 292.5 K (+3.31 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 37,500 | 198,000 | 283,127 | 245.6 K to 283.1 K (+15.27 %) |
Nov 14 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.88 | 31,543 | 185,473 | 245,627 | 214.1 K to 245.6 K (+14.73 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 27.97 | 4,550 | 127,264 | 31,850 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 8,101 | 195,315 | 16,689 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 4,182 | 29,776 | 937 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 4,210 | 101,503 | 24,790 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 2,381 | 16,953 | 5,119 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 1,115 | 5,887 | 16,761 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 10,984 | 57,996 | 0 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 3.88 | 954 | 3,702 | 4,561 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 7,124 | 37,615 | 17,876 | |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.14 | 16,833 | 574,679 | 75,866 | 92.7 K to 75.9 K (-18.16 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 27.97 | 4,550 | 127,264 | 92,699 | 88.1 K to 92.7 K (+5.16 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 8,101 | 195,315 | 88,149 | 80 K to 88.1 K (+10.12 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 4,182 | 29,776 | 80,048 | 75.9 K to 80 K (+5.51 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.00 | 28 | 952 | 75,866 | 75.9 K to 75.9 K (-0.04 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 33.37 | 19,616 | 654,586 | 75,894 | 95.5 K to 75.9 K (-20.54 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 4,210 | 101,503 | 95,510 | 91.3 K to 95.5 K (+4.61 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 2,381 | 16,953 | 91,300 | 88.9 K to 91.3 K (+2.68 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 1,115 | 5,887 | 88,919 | 87.8 K to 88.9 K (+1.27 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 10,984 | 57,996 | 87,804 | 76.8 K to 87.8 K (+14.30 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 3.88 | 954 | 3,702 | 76,820 | 75.9 K to 76.8 K (+1.26 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.98 | 1,561 | 54,604 | 75,866 | 77.4 K to 75.9 K (-2.02 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.31 | 14,448 | 495,711 | 77,427 | 91.9 K to 77.4 K (-15.73 %) |
Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 7,124 | 37,615 | 91,875 | 84.8 K to 91.9 K (+8.41 %) |
Oct 04 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.50 | 857,145 | 30,428,648 | 453,505 | 1.3 M to 453.5 K (-65.40 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 3.88 | 11,500 | 44,620 | 5,000 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 24.11 | 13,671 | 329,608 | 15,329 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 7.12 | 781 | 5,561 | 1,562 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 38.05 | 45,952 | 1,748,474 | 56,223 | 102.2 K to 56.2 K (-44.97 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 3.88 | 11,500 | 44,620 | 102,175 | 90.7 K to 102.2 K (+12.68 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 24.11 | 13,671 | 329,608 | 90,675 | 77 K to 90.7 K (+17.75 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 7.12 | 781 | 5,561 | 77,004 | 76.2 K to 77 K (+1.02 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 7.12 | 4,688 | 33,379 | 2,343 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 5.28 | 6,250 | 33,000 | 0 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 3.88 | 5,500 | 21,340 | 16,500 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 32.14 | 21,438 | 689,017 | 76,223 | 97.7 K to 76.2 K (-21.95 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 7.12 | 4,688 | 33,379 | 97,661 | 93 K to 97.7 K (+5.04 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 5.28 | 6,250 | 33,000 | 92,973 | 86.7 K to 93 K (+7.21 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 3.88 | 5,500 | 21,340 | 86,723 | 81.2 K to 86.7 K (+6.77 %) |
Aug 11 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 7.12 | 17,000 | 121,040 | 8,000 | |
Aug 11 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.28 | 1,896 | 10,011 | 0 | |
Aug 11 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 7.12 | 17,000 | 121,040 | 98,500 | 81.5 K to 98.5 K (+20.86 %) |
Aug 11 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.28 | 1,896 | 10,011 | 81,500 | 79.6 K to 81.5 K (+2.38 %) |
Jul 25 2016 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 32.98 | 20,000 | 659,600 | 20,000 | |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.28 | 6,000 | 31,680 | 1,896 | |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.28 | 6,000 | 31,680 | 79,604 | 73.6 K to 79.6 K (+8.15 %) |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 4,421 | 23,343 | 1,883 | |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 4,421 | 23,343 | 131,577 | 127.2 K to 131.6 K (+3.48 %) |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 16,251 | |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 62,600 | 57.6 K to 62.6 K (+8.68 %) |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 1.80 | 95,000 | 171,000 | 0 | |
Jul 07 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 1.80 | 95,000 | 171,000 | 214,084 | 119.1 K to 214.1 K (+79.78 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.28 | 4,604 | 24,309 | 7,896 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 3.88 | 3,500 | 13,580 | 0 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 5,896 | 29,952 | 0 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 34.89 | 20,207 | 705,022 | 73,604 | 93.8 K to 73.6 K (-21.54 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 34.20 | 5,793 | 198,121 | 93,811 | 99.6 K to 93.8 K (-5.82 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.28 | 4,604 | 24,309 | 99,604 | 95 K to 99.6 K (+4.85 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 3.88 | 3,500 | 13,580 | 95,000 | 91.5 K to 95 K (+3.83 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 5,896 | 29,952 | 91,500 | 85.6 K to 91.5 K (+6.89 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 3,966 | 20,940 | 6,304 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 18,095 | 95,542 | 10,270 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 10,209 | 39,611 | 0 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 34.13 | 500 | 17,065 | 127,156 | 127.7 K to 127.2 K (-0.39 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 32.89 | 3,466 | 113,997 | 127,656 | 131.1 K to 127.7 K (-2.64 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 3,966 | 20,940 | 131,122 | 127.2 K to 131.1 K (+3.12 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 34.77 | 28,304 | 984,130 | 127,156 | 155.5 K to 127.2 K (-18.21 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 18,095 | 95,542 | 155,460 | 137.4 K to 155.5 K (+13.17 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 10,209 | 39,611 | 137,365 | 127.2 K to 137.4 K (+8.03 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 5.28 | 15,300 | 80,784 | 9,400 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 34.66 | 25,300 | 876,898 | 57,600 | 82.9 K to 57.6 K (-30.52 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 5.28 | 15,300 | 80,784 | 82,900 | 67.6 K to 82.9 K (+22.63 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 41,477 | 218,999 | 42,500 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 30,501 | 161,045 | 83,977 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.28 | 23,022 | 121,556 | 114,478 | |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.26 | 10,437 | 357,572 | 119,084 | 129.5 K to 119.1 K (-8.06 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.58 | 31,040 | 1,042,323 | 129,521 | 160.6 K to 129.5 K (-19.33 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 41,477 | 218,999 | 160,561 | 119.1 K to 160.6 K (+34.83 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.22 | 2,390 | 81,786 | 119,084 | 121.5 K to 119.1 K (-1.97 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.18 | 28,111 | 932,723 | 121,474 | 149.6 K to 121.5 K (-18.79 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 30,501 | 161,045 | 149,585 | 119.1 K to 149.6 K (+25.61 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.92 | 20,626 | 720,260 | 119,084 | 139.7 K to 119.1 K (-14.76 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.18 | 7,396 | 252,795 | 139,710 | 147.1 K to 139.7 K (-5.03 %) |
Jul 06 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.28 | 23,022 | 121,556 | 147,106 | 124.1 K to 147.1 K (+18.55 %) |
May 25 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 5.28 | 300 | 1,584 | 24,700 | |
May 25 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 34.00 | 25,300 | 860,200 | 67,600 | 92.9 K to 67.6 K (-27.23 %) |
May 25 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 5.28 | 300 | 1,584 | 92,900 | 92.6 K to 92.9 K (+0.32 %) |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 25,787 | 130,998 | 114,633 | |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 37,623 | 191,125 | 140,420 | |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 24,090 | 122,377 | 178,043 | |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.17 | 25,787 | 855,355 | 124,084 | 149.9 K to 124.1 K (-17.21 %) |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 25,787 | 130,998 | 149,871 | 124.1 K to 149.9 K (+20.78 %) |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.04 | 37,623 | 1,243,064 | 124,084 | 161.7 K to 124.1 K (-23.27 %) |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 37,623 | 191,125 | 161,707 | 124.1 K to 161.7 K (+30.32 %) |
May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.04 | 36,590 | 1,208,934 | 124,084 | 160.7 K to 124.1 K (-22.77 %) |